Teleflex (NYSE:TFX) Stock, Quote.Headers.trade-ideas

Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Biotech

Earnings

Earnings Beats

Large Cap

News

Guidance

Markets

Analyst Ratings

Trading Ideas

General

Teleflex Incorporated (NYSE: TFX) posted adjusted earnings per share from continuing operations of $3.42 in the second quarter of 2024, up 0.3% from the year-ago quarter&#39;s figure. The metric topped the Zacks Consensus Estimate by 2.7%.

Teleflex Tops Q2 Earnings Estimates, Raises 2024 Outlook

Stuttgart,,Germany,-,08-11-2023:,Person,Holding,Cellphone,With,Logo,Of

Analyst Color

Long Ideas

Upgrades

Price Target

Movers

Teleflex gets an upgraded rating. Analyst Matt O&#39;Brien takes it from Neutral to Overweight, and raises the price target from $205 to $245.

This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst

Health Care

Teleflex (NYSE: TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business.

Is it Wise to Hold Teleflex Stock in Your Portfolio Now?

Teleflex Inc

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has fallen 43.78% since its last report. The company recently reported that it has 361 thousand shares sold short, which is 1.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724694321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.60%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Teleflex?

Teleflex Announces A Review Showing That The Titan SGS Stapler Offers Consistent Gastric Pouch Formation With Fewer Variations, Potentially Enhancing Clinical Outcomes And Procedural Efficiency Compared To Traditional Staplers

RBC Capital analyst Shagun Singh reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and maintains $260 price target.

Reiteration

RBC Capital Reiterates Outperform on Teleflex, Maintains $260 Price Target

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and raises the price target from $240 to $247.

Truist Securities Maintains Hold on Teleflex, Raises Price Target to $247

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $254.0, a high estimate of $290.00, and a low estimate of $235.00. Observing a 8.64% increase, the current average has risen from the previous average price target of $233.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1722632409_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Teleflex. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$235.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$205.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teleflex. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Teleflex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Teleflex's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teleflex analyst ratings.</a>
<h2>All You Need to Know About Teleflex</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>Financial Insights: Teleflex</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Teleflex displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 3.79%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.34%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Teleflex's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Teleflex Stock

RBC Capital analyst Shagun Singh maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and raises the price target from $235 to $260.

RBC Capital Maintains Outperform on Teleflex, Raises Price Target to $260

Stephens &amp; Co. analyst George Sellers maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Overweight and raises the price target from $275 to $290.

Stephens & Co. Maintains Overweight on Teleflex, Raises Price Target to $290

Teleflex Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tfx#NYSE">TFX</a>) posted adjusted earnings per share from continuing operations of $3.42 in the second quarter of 2024, up 0.3% from the year-ago quarter&#39;s figure. The metric topped the Zacks Consensus Estimate by 2.7%.
GAAP EPS came in at $1.69 in the second quarter compared with $2.35 during the same period last year.
<h3>Revenues in Detail</h3>
Net revenues in the second quarter rose 0.9% year over year (up 3.4% at constant exchange rate or CER) to $749.7 million. However, the metric missed the Zacks Consensus Estimate by 1.8%.
Segmental Details
Americas&#39; net revenues of $426.8 million increased 0.5% from the year-ago period&#39;s levels (up 0.6% at CER). This compares with our model&#39;s projection of $436.2 million for the second quarter. In the prior year, MSA revenues were booked in the Americas, which resulted in a tough year-over-year comparison. Management stated that the impact of the MSA termination in the second quarter was similar to the first quarter.
EMEA&#39;s (Europe, the Middle East and Africa) net revenues of $147.1 million fell 0.5% year over year (up 9.8% at CER). Our model projected revenues to be $158.7 million in the second quarter. The growth was driven by a targeted strategy to increase the geographic availability of Teleflex products and improve utilization in Europe.
Revenues from Asia (Asia Pacific) rose 0.4% to $83.7 million (up 4% at CER). Our model&#39;s projection was $83.7 million. Revenue growth was broad-based across the region, with double-digit increases in China, India and Southeast Asia.
OEM (Original Equipment Manufacturer and Development Services) revenues were $84.9 million, an increase of 0.9% year over year (up 3.4% at CER).
<h3>Product Revenues in Detail</h3>
In the second quarter, the Vascular Access segment recorded net revenues of $181.1 million, up 4.8% year over year at CER. This compares with our model&#39;s projection of $184.4 million for the second quarter.
The Interventional business registered net revenues of $141.2 million, up 13.8% at CER from the same period last year. This compares with our model&#39;s projection of $139.9 million for the second quarter.
Within the Anesthesia segment, net revenues increased 2.3% year over year at CER to $102.5 million. This compares with our model&#39;s projection of $105.1 million for the second quarter.
<div class="chart_embed">
<h3>Teleflex Incorporated Price, Consensus and EPS Surprise</h3>
<img alt="Teleflex Incorporated Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/40/1722586620.png" style="height:265px; width:590px" title="" />
Teleflex Incorporated price-consensus-eps-surprise-chart | Teleflex Incorporated Quote
The Surgical segment recorded net revenues of $111.3 million, up 6.4% year over year at CER. This came in line with our model&#39;s projected figure for the second quarter.
</div>
Revenues from the Interventional Urology segment were $83.1 million, up 7.1% year over year. This compares with our model&#39;s projection of $81.1 million for the second quarter.
OEM&nbsp;recorded revenue growth of $88.8 million, up 5.8% from the year-ago figure. This compares with our model&#39;s projection of $86.8 million for the second quarter.
The Other product segment&#39;s (consisting of the company&#39;s respiratory products not included in the divestiture to Medline, manufacturing service agreement revenues and Urology Care products) net revenues of $41.7 million registered a year-over-year decline of 26.4%. This compares with our model&#39;s projection of $54.8 million for the second quarter.
<h3>Margins</h3>
In the reported quarter, the gross profit totaled $416.5 million, up 2.1% year over year. The gross margin expanded 68 basis points (bps) to 55.6% due to a 0.7% fall in the cost of goods sold.
Overall, the adjusted operating profit was $124.7 million, down 14% year over year. The adjusted operating margin saw a 288 bps contraction year over year to 16.6%.
<h3>Liquidity Position</h3>
Teleflex exited the second quarter of 2024 with cash and cash equivalents of $238.6 million compared with $237.4 million at the end of the first quarter.
Cumulative cash flow provided by operating activities from continuing operations was $204.5 million compared with $170.6 million in the year-ago period.
In conjunction with the earnings release, the company announced that its board of directors has authorized a share repurchase program for up to $500 million of common stock, including the commencement of an accelerated share repurchase program for $200 million. The program will take effect on Aug 2, 2024.
<h3>2024 View</h3>
Teleflex updated its financial guidance for 2024.
GAAP revenue growth for 2024 is expected in the range of 3.40%-4.40% (previously 3.35%-4.35%). The company&#39;s constant currency revenue growth expectation for 2024 has been increased to 4.25%-5.25% (earlier 3.75%-4.75% range). The Zacks Consensus Estimate for total revenues is pegged at $3.09 billion.
Teleflex has raised its 2024 adjusted EPS from continuing operations to a new range of $13.80-$14.20 (from the earlier band of 13.60-$13.95). The Zacks Consensus Estimate is currently pegged at $13.75.
<h3>Our Take</h3>
Teleflex delivered better-than-expected earnings in the second quarter of 2024, while revenues missed estimates. However, performance was consistent with the company&#39;s ongoing strategy to grow durable revenues. The broad portfolio of vascular access drove the year-over-year growth in revenues, including the PICC portfolio and central access. The underlying trends in the surgical franchise were solid, with growth in the company&#39;s largest franchises led by instrumentation and chest drainage.
Additionally, the Interventional business continued to perform well, including contributions from growth drivers such as MANTA, complex catheters, right heart catheters and intra-aortic balloon pumps. Revenue momentum for Barrigel remained strong, and the integration of Palette Life Sciences AB is also on track. The gross margin expansion in the quarter looks optimistic. Also, the upbeat revised guidance for the full year is highly encouraging.
Meanwhile, within Asia, Teleflex&#39;s business in South Korea posted a softer performance due to the ongoing impact of the doctors&#39; strike.
<h3>Zacks Rank and Key Picks</h3>
Teleflex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical, Abbott Laboratories, Inc. and Quest Diagnostics.
Intuitive Surgicalreported a third-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgicalhas an estimated long-term earnings growth rate of 16.1% in 2024 compared with the industry&#39;s 14.1%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 8.97%.
Abbott, carrying a Zacks Rank #2 (Buy), reported third-quarter 2024 earnings of $1.14, which surpassed the Zacks Consensus Estimate by 3.6%. Revenues of $10.38 billion topped the Zacks Consensus Estimate by 0.3%.&nbsp;
ABT has an estimated earnings growth rate of 10.1% for 2025 compared&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with the S&amp;P 500&#39;s 9.3%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 2.34%.
Quest Diagnostics, carrying a Zacks Rank #2, reported a third-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion exceeded the Zacks Consensus Estimate by 0.5%.
DGX&#39;s historical five-year earnings growth rate of 7.4% compared favorably with the industry&#39;s 4.2%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 3.31%.
<a href="https://www.zacks.com/stock/news/2314994/teleflex-tfx-tops-q2-earnings-estimates-raises-2024-outlook?cid=CS-BENZ-FT-analyst_blog|earnings_article-2314994">To read this article on Zacks.com click here.</a>

Teleflex Expects 2024 Adjusted EPS Of $13.80-$14.20 Versus Prior Guidance Of $13.60-$13.95 And Consensus Of $13.73

Teleflex Raises GAAP Revenue Growth Guidance Range To 3.40%-4.40% From Prior Guidance Of  3.35%-4.35%, Sees Adjusted Constant Currency Revenue Growth Of 4.25%-5.25% Versus Prior Guidance Of 3.75%-4.75%

Teleflex Q2 2024 Adj. EPS $3.42 Beats $3.33 Estimate, Sales $749.691M Miss $764.562M Estimate

Teleflex Announced U.S. Food And Drug Administration (FDA) 510(k) Clearance Of The Ringer Perfusion Balloon Catheter, The Only Commercially Available Percutaneous Transluminal Coronary Angioplasty Perfusion Balloon

Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc. Effective July 1, 2024, the Premier National Hemostasis Products and SURPASS&reg; Hemostasis Products agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex products within the hemostatic portfolio. 
&nbsp;
Premier&#39;s SURPASS&reg; program is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services. The program brings together Premier&#39;s most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing.
QuikClot&trade; Hemostatic Dressings and Devices control bleeding faster than standard gauze or laparotomy pads,1-3&nbsp;enabling clinicians to move patients to the next stage of care quickly. The portfolio includes a range of products to support clinicians throughout the hospital, including in the Emergency Department, Operating Room, Intensive Care Unit, and Catheterization Lab.

PINC

Teleflex Secures Premier Agreements for Hemostasis Products with Special Pricing

Teleflex Announced The Establishment Of The Teleflex Center For Antimicrobial Protection As A Strategic Branch Of Its Vascular Access Business Unit Led By Chuck Gartner, Director Of Marketing - Strategic Initiatives

Analysts' ratings for Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $234.75, along with a high estimate of $245.00 and a low estimate of $219.00. Surpassing the previous average price target of $224.75, the current average has increased by 4.45%.
<img src="https://www.benzinga.com/files/images/story/2024/1721163714_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Teleflex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$235.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$219.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teleflex. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teleflex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Teleflex's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teleflex analyst ratings.</a>
<h2>Get to Know Teleflex Better</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>Teleflex: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Teleflex's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.79% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.34%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Teleflex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.2%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.41, Teleflex adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Teleflex Through 4 Analysts

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and raises the price target from $235 to $240.

Truist Securities Maintains Hold on Teleflex, Raises Price Target to $240

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has fallen 8.73% since its last report. The company recently reported that it has 620 thousand shares sold short, which is 2.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720710911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(TFX) - Analyzing Teleflex's Short Interest

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and raises the price target from $219 to $235.

Truist Securities Maintains Hold on Teleflex, Raises Price Target to $235

Teleflex Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) benefited in the first quarter from the <a href="https://www.benzinga.com/news/earnings/24/06/39548980/is-it-wise-to-hold-teleflex-stock-in-your-portfolio-now">surge in the interventional segment and other tailwinds</a>.
UroLift sales in the physician's office could bottom out at $49 million in 2024 and the franchise will be "less of a revenue headwind" from 2025, according to Piper Sandler.
The Teleflex Analyst: Matt O&#8217;Brien upgraded the rating for Teleflex from Neutral to Overweight, while raising the price target from $205 to $245.
The Teleflex Thesis: UroLift sales, which has prevented the stock from performing in recent quarters, should trough in the second or third quarter this year, O&#8217;Brien said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The company's sole competitor in the IABP market, Getinge is "facing significant regulatory issues with its production and sale of product, which makes about $170M worth of annual revenue potentially available to Teleflex," the analyst wrote.
He added that the impact of this could be felt in 2025, adding about 100-200 basis points to revenue and earnings growth.
"We continue to get good feedback on the Barrigel product that TFX acquired last year and believe this product could grow north of 20% for several years," O&#8217;Brien further stated.
TFX Price Action: Shares of Teleflex had risen by 1.7% to $213.92 at the time of publication on Monday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/07/39577351/trump-granted-partial-immunity-by-supreme-court-ruling-says-the-president-is-not-above-the-law-d">Trump Granted Partial Immunity By Supreme Court, Ruling Says &#8216;The President Is Not Above The Law&#8217;: Dissenting Justice Criticizes Mockery Of Constitution</a></li>
</ul>

Piper Sandler analyst Matt O'Brien upgrades Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Neutral to Overweight and raises the price target from $205 to $245.

Piper Sandler Upgrades Teleflex to Overweight, Raises Price Target to $245

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Teleflex (TFX – Research Report), with a price targ...

RBC Capital Remains a Buy on Teleflex (TFX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insulet (PODD – Research Report), Applied Therapeuti...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Small-cap and mid-cap Health Care has room to rally - Roth MKM

'Bottom-fishing' ideas within Piper Sandler's universe of stocks

Least shorted S&P 500 stocks in July

Russell 1000 stocks with the largest increase in hedge fund ownership in 2Q - GS

Teleflex Reinvesting In Growth, But Valuation Isn't That Compelling

Morgan Stanley analyst Patrick Wood maintained a Buy rating on Teleflex (TFX – Research Report) on September 6 and set a price target of $275.00. P...

Teleflex's Stock Buy Rating: Diverse Portfolio and Strategic Market Advantages Propel Growth

Janus Henderson Enterprise Fund Q2 2024 Commentary

Janus Henderson Contrarian Fund Q2 2024 Commentary

AAPL

ABBV

ACHC

ADMA

AEMB

AGIO

AHYB

AKAM

AMPH

AMZN

ANAB

ANET

APLT

ASTS

AVGO

BCRX

BDTX

BIRK

BKNG

BLFS

CNSWF

DXCM

EPAM

ESGA

ESGY

FLEX

FUSI

GDDY

GEHC

GMED

GNGBF

GNGBY

GOOG

GOOGL

GTLS

HALO

HRMY

HUBS

IFCZF

IFZZF

ILMN

INFFF

INSP

INTAF

JAZZ

JBHT

KORP

LGND

MASI

MLAB

MRVL

MTCH

NXPI

OMCL

ONTO

ORCL

PCTY

PODD

PRCT

PSCH

QCOM

QCON

QGRO

QINT

QPFF

REGN

RVTY

SDSI

SKIN

SKYT

SMCI

SPGI

SRCL

SSNC

SUPN

TAXF

TRMB

TWLO

VALQ

VEEV

WDAY

YETI

Press Releases

Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray

Teleflex Publishes 2023 Global Impact Report

Teleflex Announces Second Quarter 2024 Earnings Conference Call Information

Teleflex Announces the Teleflex Center for Antimicrobial Protection

Contracts

Teleflex Awarded Hemostasis Products Agreements with Premier, Inc.

Teleflex Expands Interventional Cardiology Portfolio with FDA 510(k) Clearance of the Ringer™ Perfusion Balloon Catheter

Teleflex Reports Second Quarter Financial Results and Full Year 2024 Outlook

Dividends

Teleflex Announces Quarterly Dividend

Teleflex Announces Publication of a Propensity Matching Review of Retrospective Data Reporting that the Titan SGS™ Stapler Enables Consistent Gastric Pouch Formation with Fewer Variations, Providing Potentially Enhanced Clinical Outcomes and Significant Procedural Efficiency Compared with Traditional Surgical Staplers

Teleflex to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Teleflex

Teleflex (TFX) Forecast

Teleflex (NYSE:TFX) Stock, Quote.Headers.trade-ideas